A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

Sponsor
Janssen Pharmaceutica N.V., Belgium
Study ID
NCT05049798
Status
Active Not Recruiting

Conditions

  • Arthritis, Psoriatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Guselkumab — DRUG
    Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
  • IL-17i — DRUG
    Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.

Study Details

The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).

Key Dates

Start date
Aug 25, 2021
Status verified
Jun 2026
Primary completion
Aug 1, 2027
Completion
Aug 2, 2027

Study Design

Enrollment
1,314 participants (actual)

Arms

  • Arm: Cohort 1: Guselkumab
    Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
  • Arm: Cohort 2: Interleukin-17 inhibitor (IL-17i)
    Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.

Primary Outcome Measure

The Start and Stop Date of Guselkumab, as Applicable, For Each Participant [ Time Frame: Up to 39 months ]

Related Studies